<DOC>
	<DOCNO>NCT01489046</DOCNO>
	<brief_summary>The purpose study identify least one dose BMS-986001 safe , well tolerate , efficacious combine Efavirenz ( EFV ) + Lamivudine ( 3TC ) treatment-naive Human Immunodeficiency Virus 1 ( HIV-1 ) infect subject</brief_summary>
	<brief_title>Safety , Efficacy Dose-response Study BMS-986001 Subjects With HIV-1 Infection Who Are Treatment-naive</brief_title>
	<detailed_description>Double Blind Week 24 . Partially Blind ( subject , caregiver , Investigators ) Week 48 .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>At least 18 year age , ( minimum age determine local regulatory legal requirement dictate , whichever high ) Plasma HIV1 RNA &gt; 5000 copies/mL Antiretroviral treatmentnaive ; define current previous exposure &gt; 1 week antiretroviral drug CD4+ Tcell count &gt; 200 cells/mm3 Resistance study medication [ Tenofovir Disoproxil Fumarate ( TDF ) , Efavirenz ( EFV ) , Lamivudine ( 3TC ) ] HIV Protease Inhibitors ( PIs ) Contraindications study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>